The WHO Collaborating Center for Urologic Tumors, Karolinska
Conferences | Conference 2010 

The WHO Center for Urologic Tumors Conference 2010

Prostate Cancer: Screening, Prevention and Therapy –
Lessons Learnt from Current Trials

8–10 September 2010.

This conference was EU-ACME accredited

Venue: Hasselbacken, Stockholm, Sweden

 

Proceedings from the Conference (pdf file, 2,3 MB)

 

Program

as of 26 Aug 2010

Wednesday 8 Sept 2010
19.00–21.00 Registration and Get together, faculty, conference venues
Thursday 9 Sept 2010
08.00–11.00 Expert committee meeting, Faculty
11.00 Registration
11.30–13.00 Lunch
13.00–13.10 Introduction, Sten Nilsson, Stockholm
13.10–14.45

Early detection, screening.
Chairman: Lars Holmberg, London
Co-chairman Olof Akre, Stockholm

Screening for prostate cancer – the controversy continues, but can it be resolved?
Fritz H Schröder, Rotterdam

The Confluence of Prostate Cancer Screening in the US and the PLCO Trial
Christine D Berg, Washington, DC

Early detection of prostate cancer with emphasis on genetic markers.
Henrik Grönberg, Stockholm

Discussion

14.45–15.15 Coffee break
15.15–18.00

Assessing the tumor
Chairman Steven Joniau, Leuven    
Co-chairman Marianne Brehmer, Stockholm

State-of-the-art Uroradiologic imaging in the diagnosis of prostate cancer.
Jelle Barentsz, Nijmegen

Molecular imaging in castrate resistant prostate cancer.
Steven M. Larson, New York

Discussion    
Break

Pathology in prostate research:
I. Optimizing the pathological data.
II. Optimizing the tissue quality.

Role of histopathological and molecular markers in the active surveillance of prostate cancer.
Lars Egevad, Stockholm,
Rodolfo Montironi, Ancona,
Daniel Berney, London

Discussion   

Tumor markers in prostate cancer: diagnostic and prognostic tissue biomarkers.
Anders Bjartell, Malmö

Discussion

19.30– Dinner (informal), Solliden Restaurant, Skansen
Friday 10 Sept 2010
08.30–10.30

Therapy with curative intent.
Chairman Peter Wiklund, Stockholm
Co-chairman Anders Ullén, Stockholm

Radical prostatectomy. An overview of outcome and side effects.
Jonas Hugosson, Göteborg   
Radiotherapy. Anders  Widmark, Umeå  
Surgery or radiotherapy for clinically localised prostate cancer.
Freddie Hamdy, Oxford  

Discussion

10.30–11.00 Coffee break
11.00–12.30

Natural history of prostate cancer. Active surveillance.
Chairman Ola Bratt, Lund
Co-chairman  Martin Schumacher, Stockholm

When is active surveillance the appropriate treatment for prostate cancer?
Peter C. Albertsen, Farmington

Discussion

Chemoprevention of prostate cancer.
Roger S Rittmaster, Durham

Discussion  
12.30–14.00 Lunch
14.00–15.00

Management of advanced disease. New drugs.
Chairman Ziya Kirkali, Izmir
Co-chairman  Anders Ullén, Stockholm

Broadening horizons in medical management of prostate cancer.
Ian Tannock, Toronto

Discussion

15.00–15.40

Prostate cancer from the horizon of the patient. 

Prostate cancer from the horizon of the patient.
Louis Denis, Antwerp

Discussion

15.40–16.00

Lessons learnt and goals in sight

Recent progress and future challenges in the management of prostate cancer.
Peter C. Albertsen 

18.15 Visit Nobel Museum, with dinner (informal)

 

Information

WHO Collaborating Center for Urologic Tumors
Department of Oncology (Radiumhemmet)
Karolinska University Hospital
SE- 171 76 Stockholm, Sweden
Tel +46 8 5177 2123
Fax +46 8 307771
E-mail: eva.gripenholm@ki.se

Stockholm, Sweden
Stockholm, Sweden

© 2020, WHO Center for Urologic Tumors | Latest changed 12.9.2011